Cumulative Meta-Analysis of the Soy Effect Over Time

Area of Science:

• Nutrition Science
• Cardiovascular Health
• Dietary Interventions

Background:

• Soy protein foods are recognized for mild cholesterol-lowering effects, suitable for therapeutic diets.
• Inconsistent findings in previous trials led the US Food and Drug Administration (FDA) to re-evaluate the 1999 soy heart health claim.
• A reassessment was prompted by variability in soy's impact on cholesterol levels across studies.

Purpose of the Study:

• To conduct a cumulative meta-analysis of 46 randomized controlled trials on soy protein and cholesterol.
• To determine if the cholesterol-lowering effect of soy lost statistical significance since the 1999 FDA health claim approval.
• To evaluate the long-term significance of soy consumption on serum cholesterol levels.

Main Methods:

• Cumulative meta-analysis of 46 randomized controlled trials identified by the FDA.
• Analysis focused on total cholesterol and low-density lipoprotein (LDL) cholesterol levels.
• Statistical significance was assessed at multiple time points since 1999.

Main Results:

• Cumulative meta-analysis demonstrated sustained, significant reductions in total cholesterol and LDL cholesterol.
• Mean LDL cholesterol reduction in 1999 was -6.3 mg/dL, remaining significant (-4.2 to -6.7 mg/dL) in subsequent years.
• No time point evaluated showed a loss of statistical significance for cholesterol reduction, nor were differences significantly different from 1999 levels.

Conclusions:

• The FDA-selected data indicate that soy consumption continues to significantly reduce total cholesterol and LDL cholesterol.
• Findings support the scientific basis for the original FDA heart health claim for soy protein.
• Soy protein remains a beneficial dietary component for managing cholesterol levels.